Table 2 Factors that impact the serum level of IgG-S1 antibodies against SARs-CoV-2 in samples of individuals after recovering from the first infection of COVID-19
From: A stronger antibody response in increased disease severity of SARS-CoV-2
Variables | IgG Antibody | p-value |
|---|---|---|
Median (Q1; Q3) | ||
Hospitalization | ||
Yes | 6.76 (4.98; 8.14) | < 0.001* |
No | 2.67 (1.18; 4.74) | |
Sex | ||
Male | 4.95 (1.73; 7.33) | 0.033* |
Female | 3.70 (1.90; 6.07) | |
Obesity | ||
Yes | 4.96 (2.49; 6.81) | 0.014* |
No | 3.62 (1.47; 6.78) | |
Symptoms at diagnosis | ||
1–3 | 3.92 (1.32; 6.70) | 0.026** |
4–5 | 5.02 (2.67; 7.38) | |
≥ 6 | 4.16 (1.82; 6.31) | |
Age (in years) | ||
18 to 45 | 2.20 (1.01; 4.08) | < 0.001** |
46 to 59 | 5.33 (2.60; 6.98) | |
60 or over | 5.65 (3.19; 7.45) | |
SAH | ||
Yes | 5.85 (3.26; 7.42) | < 0.001* |
No | 3.27 (1.42; 5.83) | |
T2DM | ||
Yes | 5.97 (3.94; 7.64) | < 0.001* |
No | 3.81 (1.58; 6.29) | |
IgG antibody titers in DASO | ||
Up to 90 DASO | 6.20 (3.43; 8.08) | < 0.001** |
91 to 180 DASO | 3.82 (2.05; 6.10) | |
> 180 DASO | 2.63 (1.25; 5.01) | |